| Literature DB >> 28608836 |
Sodik Numonov1,2, Salamet Edirs3,4, Khayrulla Bobakulov5, Muhammad Nasimullah Qureshi6, Khurshed Bozorov7,8, Farukh Sharopov9,10, William N Setzer11, Haiqing Zhao12, Maidina Habasi13, Mizhgona Sharofova14, Haji Akber Aisa15.
Abstract
The root of Geranium collinum Steph is known in Tajik traditional medicine for its hepatoprotective, antioxidant, and anti-inflammatory therapeutic effects. The present study was conducted to evaluate of potential antidiabetic, antioxidant activities, total polyphenolic and flavonoid content from the different extracts (aqueous, aqueous-ethanolic) and individual compounds isolated of the root parts of G. collinum. The 50% aqueous-ethanolic extract possesses potent antidiabetic activity, with IC50 values of 0.10 μg/mL and 0.09 μg/mL for the enzymes protein-tyrosine phosphatase (1B PTP-1B) and α-glucosidase, respectively. Phytochemical investigations of the 50% aqueous-ethanolic extract of G. collinum, led to the isolation of ten pure compounds identified as 3,3',4,4'-tetra-O-methylellagic acid (1), 3,3'-di-O-methylellagic acid (2), quercetin (3), caffeic acid (4), (+)-catechin (5), (-)-epicatechin (6), (-)-epigallocatechin (7), gallic acid (8), β-sitosterol-3-O-β-d-glucopyranoside (9), and corilagin (10). Their structures were determined based on 1D and 2D NMR and mass spectrometric analyses. Three isolated compounds exhibited strong inhibitory activity against PTP-1B, with IC50 values below 0.9 μg/mL, more effective than the positive control (1.46 μg/mL). Molecular docking analysis suggests polyphenolic compounds such as corilagin, catechin and caffeic acid inhibit PTP-1B and β-sitosterol-3-O-β-d-gluco-pyranoside inhibits α-glucosidase. The experimental results suggest that the biological activity of G. collinum is related to its polyphenol contents. The results are also in agreement with computational investigations. Furthermore, the potent antidiabetic activity of the 50% aqueous-ethanolic extract from G. collinum shows promise for its future application in medicine. To the best of our knowledge, we hereby report, for the first time, the antidiabetic activity of G. collinum.Entities:
Keywords: Geranium collinum Steph; NMR; PTP-1B; molecular docking; polyphenolic compounds; α-glucosidase
Mesh:
Substances:
Year: 2017 PMID: 28608836 PMCID: PMC6152703 DOI: 10.3390/molecules22060983
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Graphical comparison of the yields of different extractions of the roots of G. collinum.
Figure 2Chemical structures of the major compounds isolated from 50% ethanol extract of Geranium collinum.
Results of the total polyphenolic compounds, total flavonoids, antioxidant and antidiabetic activities.
| Sample | Total Polyphenolic Compounds, mg GAE/g Extract | Total Flavonoids, mg QE/g Extract | Antioxidant Activity IC50 Values (μg/mL) | Antidiabetic Activity (PTP-1B) IC50 Values (μg/mL) | Antidiabetic Activity (α-Glucosidase) IC50 Values (μg/mL) |
|---|---|---|---|---|---|
| H2O | 12.21 ± 0.10 | 3.31 ± 0.04 | 15.17 ± 0.84 | 0.13 ± 0.01 | 0.11 ± 0.01 |
| 30% EtOH | 83.74 ± 0.18 | 42.77 ± 0.12 | 10.89 ± 0.63 | 0.29 ± 0.02 | 0.10 ± 0.01 |
| 50% EtOH | 349.84 ± 0.21 | 96.07 ± 0.08 | 11.21 ± 0.49 | 0.10 ± 0.01 | 0.07 ± 0.01 |
| 70% EtOH | 180.14 ± 0.11 | 75.31 ± 0.07 | 12.69 ± 0.6 | 0.16 ± 0.01 | 0.09 ± 0.01 |
| EtOH absolute | 100.42 ± 0.14 | 55.68 ± 0.02 | 11.23 ± 0.7 | 0.43 ± 0.02 | 1.98 ± 0.21 |
| Vitamin C | 5.34 ± 0.42 | ||||
| PTP-1B a inhibitor | 1.46 ± 0.40 | ||||
| α-Glucosidase b | 2.19 ± 0.04 |
Note: a—PTP-1B-enzyme inhibitor (3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran-6-sulfonic acid-(4-(thiazol-2-ylsulfamyl)-phenyl)-amide); b—α-glucosidase enzyme inhibitor (acarbose).
In vitro antidiabetic activity (as IC50 values) of isolated major compounds from Geranium collinum.
| Name of Compounds | Antidiabetic Activity | |
|---|---|---|
| (PTP-1B) IC50 Values (μg/mL) | (α-Glucosidase) IC50 Values (μg/mL) | |
| 3,3′,4,4′-Tetra- | 21.64 ± 1.19 | No effect |
| 3,3′-Di- | 6.26 ± 0.22 | No effect |
| Caffeic acid | 35.81 ± 1.62 | 22.49 ± 1.12 |
| Quercetin | 2.19 ± 0.2 | 4.15 ± 0.19 |
| Catechin | 0.62 ± 0.06 | 4.65 ± 0.20 |
| Epicatechin | 0.23 ± 0.04 | 2.62 ± 0.12 |
| Epigallocatechin | No effect | 42.44 ± 2.15 |
| Gallic acid | No effect | 68.30 ± 3.02 |
| Daucosterol | No effect | 30.19 ± 1.56 |
| Corilagin | 0.87 ± 0.09 | 5.59 ± 0.37 |
| PTP-1B a and acarbose b | 1.46 ± 0.40 | 2.19 ± 0.11 |
Note: a—PTP-1B-enzyme inhibitor (3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran-6-sulfonic acid-(4-(thiazol-2-ylsulfamyl)-phenyl)-amide); b—α-glucosidase enzyme inhibitor (acarbose).
Molegro docking energies (re-rank scores, Edock) and normalized docking scores (DSnorm), kJ/mol, for Geranium collinum phytochemicals with human protein tyrosine phosphatase 1B and human α-glucosidase.
| Ligand | Protein Tyrosine Phosphatase 1B | α-Glucosidase | ||||||
|---|---|---|---|---|---|---|---|---|
| 3CWE a | 4Y14 b | 3LPP c | 3TOP d | |||||
| Edock | DSnorm | Edock | DSnorm | Edock | DSnorm | Edock | DSnorm | |
| Co-crystallized ligand | −87.4 | −79.5 | −125.0 | −116.1 | −116.0 | −110.9 | −130.3 | −108.3 |
| 3,3′,4,4′-Tetra- | −91.4 | −92.5 | −98.6 | −99.8 | −55.9 | −56.6 | −83.2 | −84.2 |
| 3,3′-Di- | −82.4 | −85.7 | −93.3 | −97.0 | −59.8 | −62.2 | −72.2 | −75.1 |
| Caffeic acid | −78.2 | −99.6 | −81.5 | −103.8 | −69.6 | −88.6 | −65.9 | −83.9 |
| Catechin | −86.9 | −94.3 | −86.9 | −94.4 | −77.5 | −84.1 | −83.5 | −90.7 |
| Corilagin | −111.9 | −93.7 | −101.2 | −84.4 | −107.5 | −89.9 | −120.4 | −100.8 |
| Daucosterol | −12.6 | −10.8 | −86.4 | −74.6 | −103.4 | −89.3 | −129.3 | −111.6 |
| Ellagic acid | −82.3 | −88.1 | −92.3 | −98.9 | −51.7 | −55.4 | −72.5 | −77.6 |
| Epicatechin | −87.4 | −94.9 | −95.7 | −103.9 | −76.5 | −83.1 | −82.3 | −89.4 |
| Epigallocatechin | −91.9 | −98.0 | −98.5 | −105.1 | −79.8 | −85.1 | −89.2 | −95.1 |
| Gallic acid | −75.5 | −97.9 | −78.8 | −102.3 | −70.4 | −91.3 | −67.0 | −86.9 |
| Quercetin | −93.4 | −100.0 | −92.6 | −99.2 | −84.7 | −90.7 | −87.7 | −93.9 |
a The co-crystallized ligand for PDB 3CWE is [{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)-methyl]phosphonic acid (MW = 494.243); b the co-crystallized ligand for PDB 4Y14 is 3-bromo-4-[difluoro-(phosphono)methyl]-N-methyl-Nα-(methylsulfonyl)-l-phenylalaninamide (MW = 463.189); c the co-crystallized ligand for PDB 3LPP is (1S,2R,3R,4S)-1-{(1S)-2-[(2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)tetrahydrothio-phenium-1-yl]-1-hydroxyethyl}-2,3,4,5-tetrahydroxypentyl sulfate (MW = 424.442); d the co-crystallized ligand for PDB 3TOP is α-acarbose (MW = 646.613).
Figure 3Lowest-energy docked pose of daucosterol (dark grey stick figure) with human maltase-glucoamylase (PDB 3TOP), showing the electrostatic surface of the binding site. The co-crystallized ligand, α-acarbose, is shown as a light grey stick figure.